+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Actelion Pharmaceuticals Ltd - Strategic SWOT Analysis Review

Actelion Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - The publisher's summarization of the company’s business strategy.
  • SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Actelion Pharmaceuticals Ltd (Actelion), a subsidiary of Johnson & Johnson, is a biopharmaceutical company, which discovers, develops and commercializes innovative treatments for diseases with considerable unmet medical needs. The company focuses on the development of treatments for pulmonary arterial hypertension (PAH). Its PAH franchise products include Tracleer (bosentan), Opsumit (macitentan), Veletri (epoprostenol for injection), Ventavis (iloprost)\, and Uptravi (selexipag). Its specialty product includes Zavesca (miglustat). Actelion also offers approved treatments for diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, multiple sclerosis and digital ulcers in patients with systemic sclerosis. The company offers its products in various countries across Europe, besides Japan, China, Russia, and the US, among others. Actelion is headquartered in Allschwil, Switzerland.

Reasons to Buy

  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with the publisher's detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.

Table of Contents

Section 1 - About the Company
  • Actelion Pharmaceuticals Ltd - Key Facts
  • Actelion Pharmaceuticals Ltd - Key Employees
  • Actelion Pharmaceuticals Ltd - Key Employee Biographies
  • Actelion Pharmaceuticals Ltd - Major Products and Services
  • Actelion Pharmaceuticals Ltd - History
  • Actelion Pharmaceuticals Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Actelion Pharmaceuticals Ltd - Business Description
  • Actelion Pharmaceuticals Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Actelion Pharmaceuticals Ltd - Strengths
  • Actelion Pharmaceuticals Ltd - Weaknesses
  • Actelion Pharmaceuticals Ltd - Opportunities
  • Actelion Pharmaceuticals Ltd - Threats
  • Actelion Pharmaceuticals Ltd - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
  • Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Actelion Pharmaceuticals Ltd, Recent Deals Summary
Section 4 - Appendix
  • Methodology
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Actelion Pharmaceuticals Ltd, Key Facts
  • Actelion Pharmaceuticals Ltd, Key Employees
  • Actelion Pharmaceuticals Ltd, Key Employee Biographies
  • Actelion Pharmaceuticals Ltd, Major Products and Services
  • Actelion Pharmaceuticals Ltd, History
  • Actelion Pharmaceuticals Ltd, Subsidiaries
  • Actelion Pharmaceuticals Ltd, Key Competitors
  • Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Actelion Pharmaceuticals Ltd, Recent Deals Summary
List of Figures
  • Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Actelion Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Alpex Pharma SA
  • Anavex Life Sciences Corp
  • F. Hoffmann-La Roche Ltd
  • Kyowa Kirin International Plc
  • Merck Serono SA
  • Mymetics Corp
  • Santhera Pharmaceuticals Holding AG